Beyond traditional immunoassays: LC–MS for antibody isotyping and quantitation
Tuesday 25 March 2025
08:00 [PDT] 11:00 [EDT] 15:00 [GMT]
Accelerating PK and ADA bioanalytical assay development by maximizing dynamic range and adopting generic and streamlined strategies.
This webinar introduces a technically challenging immunoaffinity LC–MS-based method for antibody isotyping and quantitation, addressing the limitations of traditional immunoassays in vaccine and biopharmaceutical development. The accurate characterization of immune responses is crucial in these fields, where conventional ligand-binding assays (LBAs) often face challenges in specificity, isotype differentiation and quantitation in complex biological matrices. This hybrid immunoaffinity liquid chromatography–mass spectrometry (LC–MS) method offers enhanced specificity, detailed isotyping and robust semi-quantitation capabilities.
We will guide attendees through the method’s development process, highlighting key innovations such as optimized immunocapture protocols, strategies for minimizing non-specific binding, and the integration of stable isotope-labeled peptides for accurate quantitation. The presentation will address challenges faced during development and solutions implemented to achieve a regulatory-compliant, fit-for-purpose assay. We will also share the validation results demonstrating the method’s suitability for application in a regulatory setting and discuss its broader implications in bioanalysis.
What will you learn?
- Vaccine development: attendees will discover how comprehensive characterization of antibody isotypes in post-vaccination immune responses can provide critical insights into immune kinetics, biomarkers of protection and vaccine efficacy.
- Anti-drug antibody (ADA) characterization: the webinar will cover precise detection and isotyping of ADAs in biopharmaceutical development, which supports immunogenicity assessments and regulatory submissions.
- LC–MS applications: attendees will gain valuable insights into leveraging LC–MS technology for immune response characterization and understand its potential to transform analytical workflows in vaccine and drug development.
Who this may interest?
-
Vaccine developers and researchers working on immunogenicity studies
-
Biopharmaceutical scientists involved in drug development and testing
-
Bioanalytical chemists and mass spectrometry specialists
-
Immunologists studying antibody responses and isotypes
Paige Malec
Senior Method Development Scientist
Labcorp Biopharma Laboratory Services (WI, USA)
Dr Paige A Malec, PhD, is a Senior Method Development Scientist at Labcorp. She received her PhD in Analytical Chemistry from the University of Michigan (MI, USA). Working in The Kennedy Group, her dissertation focused on the development and application of derivatization techniques for LC–MS/MS metabolomics. Her work contributed to publications in journals such as Nature Neuroscience and eLife, and she has received honors at multiple conferences, both domestic and abroad.
Paige brought her expertise in small molecule bioanalysis to Labcorp in 2017 and quickly established herself as a thorough and efficient Method Development Chemist. In recent years, her work has expanded to include large molecule bioanalysis, e.g. oligonucleotides, monoclonal antibodies and ADCs. She is known at Labcorp for her tenacity, attention to detail and the overall quality of her work.
When not in the lab, Paige enjoys spending time with her children, attempting to keep a peach tree alive through the harsh Wisconsin winters, and dealing with the unpredictable nature of home improvement projects in an old Victorian house.
In association with:
